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Abstract. TAS-102 is a novel oral nucleoside antitumor agent 
containing trifluridine (FTD) and tipiracil hydrochloride 
(TPI). The compound improves overall survival of colorectal 
cancer (CRC) patients who are insensitive to standard chemo-
therapies. FTD possesses direct antitumor activity since it 
inhibits thymidylate synthase (TS) and is itself incorporated 
into DNA. However, the precise mechanisms underlying 
the incorporation into DNA and the inhibition of TS remain 
unclear. We found that FTD-dependent inhibition of TS was 
similar to that elicited by fluorodeoxyuridine (FdUrd), another 
clinically used nucleoside analog. However, washout experi-
ments revealed that FTD-dependent inhibition of TS declined 
rapidly, whereas FdUrd activity persisted. The incorporation 
of FTD into DNA was significantly higher than that of other 
antitumor nucleosides. Additionally, orally administered 
FTD had increased antitumor activity and was incorporated 
into DNA more effectively than continuously infused FTD. 
When TAS-102 was administered, FTD gradually accumu-
lated in tumor cell DNA, in a TPI-independent manner, and 
significantly delayed tumor growth and prolonged survival, 
compared to treatment with 5-FU derivatives. TAS-102 
reduced the Ki-67-positive cell fraction, and swollen nuclei 
were observed in treated tumor tissue. The amount of FTD 
incorporation in DNA and the antitumor activity of TAS-102 
in xenograft models were positively and significantly corre-
lated. These results suggest that TAS-102 exerts its antitumor 
activity predominantly due to its DNA incorporation, rather 
than as a result of TS inhibition. The persistence of FTD in 
the DNA of tumor cells treated with TAS-102 may underlie its 
ability to prolong survival in cancer patients.
Introduction
Colorectal cancer (CRC) is the fourth most common cause of 
cancer-related mortality (1). The main treatments for patients 
with advanced metastatic colorectal cancer (mCRC) include 
systemic combination chemotherapies (2-7). Although the 
standard therapies are initially effective, many patients relapse 
due to the onset of drug resistance and are subsequently placed 
on salvage chemotherapy.
TAS-102 is a novel oral nucleoside antitumor agent that 
consists of trifluridine (FTD) and tipiracil hydrochloride (TPI) 
at a molar ratio of 1:0.5. FTD is the antitumor component of 
TAS-102, whereas TPI prevents degradation of FTD through 
a first-pass effect as a thymidine phosphorylase inhibitor. FTD 
is a well-known antiproliferative agent with two mechanisms 
of action; it inhibits thymidylate synthase (TS) and is also 
incorporated into DNA (8,9). Recently, TAS-102 was found 
to significantly improve overall survival of mCRC patients 
in whom systemic chemotherapy is either ineffective or not 
tolerated (10).
Since the serum half-life of FTD is relatively short after 
intravenous (i.v.) injection, split dose regimens, as well as 
single rapid bolus injections, have been used in the clinic (11). 
However, i.v. injection of FTD has been discontinued due to 
disease recurrence and prolonged toxicity (12), and the drug 
is now currently used as an ophthalmic solution for treatment 
of epithelial keratitis caused by the herpes simplex virus (13).
FTD instability in serum is a result of degradation by 
thymidine phosphorylase (TP), and therefore co-administra-
tion of TPI with FTD is employed to increase the effective 
in vivo FTD concentration (14). We previously developed a 
TAS-102 anticancer treatment regimen in which FTD was 
orally administered and combined with TPI; this approach 
significantly prolonged survival.
These clinical results suggest that the mechanism of action 
of orally administered FTD and TPI co-treatment may differ 
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from that of i.v. administration of FTD alone. We hypothesized 
that the balance between TS inhibition and DNA incorporation 
may be altered according to the FTD administration mode. 
Therefore, we examined both delivery routes in comparative 
studies to determine the mechanism by which TAS-102 exerts 
its antitumor activity.
Materials and methods
Chemicals and reagents. FTD was obtained from Yuki Gosei 
kogyo Co., Ltd. (Tokyo, japan). 5-fluoro-2'-deoxyuridine 
(FdUrd) was obtained from wako Pure Chemical Industries 
(osaka, japan). TPI was synthesized at junsei Chemical (Tokyo, 
japan). Tegafur (FT), gimeracil (CDHP) and oteracil potas-
sium (oxo) were synthesized in-house at good manufacturing 
Practice grade. Cytarabine (Ara-C) was obtained from 
Sigma-Aldrich k.k. (Tokyo, japan). gemcitabine (dFdC) 
was synthesized in-house. [6-3H] FTD (10.0 Ci/mmol), [6-3H] 
FdUrd (13.5 Ci/mmol), [5-3H] Ara-C (26.7 Ci/mmol) and [5-3H] 
dFdC (26.0 Ci/mmol) were obtained from moravek (brea, CA, 
USA).
Animals. Five-week-old male nude mice (bALb/cA jcl-nu/nu) 
were purchased from CLeA japan Inc. (Tokyo, japan) and 
maintained in accordance with the animal experimental 
regulations of Taiho Pharmaceutical Co., Ltd. Mice were 
allowed free access to a commercial diet and water (filtered 
and chlorinated) and exposed to a 12-h light/12-h dark cycle 
in a barrier facility.
Cell culture and human cancer xenografts in nude mice. Eight 
human cancer xenografts were used (CRC cell lines DLD-1, 
HT-29, HCT116, KM20C and SW480; small cell lung cancer 
cells Lu-134; breast cancer cells MC-2 and MX-1). Lu-134, 
MC-2 and MX-1 were maintained by serial transplantation 
in the dorsum of nude mice. other xenografts were estab-
lished by implantation of cultured cells before each study. 
Lu-134 and MC-2 were obtained from the Central Institute 
for experimental Animals (Tokyo, japan). NUgC-3, HT-29 
and mX-1 cells were provided by the japanese Foundation 
for Cancer Research (Tokyo, japan). DLD-1 and HCT116 
cells were obtained from Dainippon Pharmaceutical (Tokyo, 
japan). km20C cells were kindly provided by the National 
Cancer Center (Tokyo, japan). Sw480 cells were purchased 
from American Type Culture Collection (Manassas, VA, 
USA). HeLa cells were obtained from the Health Science 
Research Resources bank (Tokyo, japan). These cultured cells 
were maintained at 37˚C with 5% Co2, in the culture medium 
recommended by each provider.
Evaluation of growth inhibitory effect in vitro. HeLa cells 
were seeded in 96-well plates at 500 cells/180 µl/well in 
triplicate, pre-cultured for 24 h, and then 20 µl of each drug 
solution was added for 24 or 72 h. For the 24-h treatment, 
cells were washed with phosphate-buffered saline (PbS) after 
treatment, drug-free medium was added to each well, and the 
culture was further incubated for 48 h. Cell growth inhibi-
tion was evaluated using a Cell Counting Kit-8 (Dojindo 
Laboratories) according to the manufacturer's instructions. 
The 50% inhibitory concentration (IC50) values were calcu-
lated from the absorbance data using SAS (SAS Institute, 
Cary, NC, USA).
Measurement of dTTP in vitro. Cells were seeded in 175-cm2 
culture flasks at 1x106 cells and pre-cultured for 24 h, prior 
to treatment with test compounds. After each treatment, cells 
were collected and resuspended in 100 µl PbS, and 50 µl of 
1.26 N perchloric acid (PCA) was added to the cell suspension. 
The mixture was left on ice for 10 min and centrifuged for 
5 min at 15,000 rpm. Three hundred microliters of 0.5 N tri-n-
octylamine dissolved in CH2Cl2 was added to the supernatant 
and centrifuged for 5 min at 15,000 rpm. The supernatant 
was applied to an HPLC system (Prominence, Shimadzu 
Corporation, kyoto, japan) equipped with an oDS reverse 
phase column (250x4.6 mm, 5 µm; Phenomenex), under an 
analytical method utilizing eluent A [10 mM KH2PO4, 10 mM 
tetrabutylammonium hydroxide (TbA-oH), 0.25% methanol, 
pH 8.0], and eluent b (50 mm kH2PO4, 5.6 mm TbA-oH, 
50% methanol, pH 6.5) at a solvent flow rate of 0.80 ml/min in a 
120-min gradient elution as follows: b 60% from 0 to 10 min, 
b 60-70% from 10 to 20 min, b 70% from 20 to 45 min, b 
70-80% from 45 to 55 min, b 80% from 55 to 80 min, b 
80-100% from 80 to 90 min, b 100% from 90 to 100 min, 
b 100-60% from 100 to 101 min, and b 60% from 101 to 
120 min.
Evaluation of the nucleoside analogue levels incorporated 
into DNA in vitro. After each drug treatment, 1x106 cells were 
harvested and DNA was extracted with a DNeasy Tissue kit 
(Qiagen GmbH, Hilden, Germany). The DNA solution was 
dissolved in 10 ml of liquid scintillation fluid (ACS-II; ge 
Healthcare) to measure the radioactivity, and the quantity of 
each tritium-labeled form in the DNA was calculated. The 
DNA concentration was calculated based on the absorbance 
at 260 nm.
In vivo evaluation of antitumor activity in mice xenograft 
models. For experiments, ~8 mm3 cubic fragments of tumor 
were implanted subcutaneously into the axilla of mice. For 
preparation of the orally administered FTD solution, FTD was 
dissolved in a 0.5% aqueous solution of hydroxypropyl methyl-
cellulose (HPmC; Shin-etsu Chemical Co., Ltd., Tokyo, japan). 
The FTD solution for continuous infusion was prepared by 
dissolving FTD in physiological saline. The TAS-102 dosing 
solution was composed of FTD and TPI dissolved in a 0.5% 
aqueous solution of HPMC at a molar ratio of 1:0.5. The dose 
of TAS-102 was expressed on the basis of the amount of FTD. 
For preparation of the S-1 solution, FT, CDHP and oxo were 
dissolved in a 0.5% aqueous solution of HPmC at a molar ratio 
of 1:0.4:1. The dose of S-1 was expressed on the basis of the 
amount of FT. when the tumor volume reached ~100 mm3, the 
mice were randomly assigned into different treatment groups. 
Nude mice in the treatment group received the test compounds. 
The control group received no treatment. For continuous infu-
sion, the compound was administered with an osmotic pump 
(ALzeT osmotic pump model 1002; DUReCT Corporation, 
Cupertino, CA, USA). Tumor volume was measured twice a 
week throughout the experiments. Tumor volume and relative 
tumor volume were calculated according to the following 
formula: Tumor volume = (width)2 x (length)/2; and relative 
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tumor volume = (mean tumor volume during treatment)/ (mean 
tumor volume at the start of treatment). The following formula 
was used to calculate the antitumor effect: Tumor growth 
inhibition rate (%) = 1 - (mean relative tumor volume of the 
treatment groups/the mean relative tumor volume of the 
control group). body weight changes (bwCs) were used as a 
proxy measure of side-effects, and calculated according to the 
following formula: bwC (%) = [(bw on evaluation date) - (bw 
on grouping date)]/(bw on day grouping date) x 100. The 
tumor growth inhibition rate (IR) % on day 15 was used to 
quantify the antitumor effect. In parallel, some tumors were 
isolated, immersed in liquid nitrogen, and stored at -80˚C for 
additional experiments described below.
Analysis of FTD incorporation into the DNA of tumor tissues 
in mouse xenografts. DNA was extracted from tumors using 
the DNA Isolation kit for Cells and Tissues (Roche Diagnostics 
gmbH, Penzberg, germany). The extracted DNA was diluted 
to 500 µg/ml with ddH2O and degraded to nucleosides in a 
200-µl reaction mixture consisting of 100 mm Tris-HCl 
(pH 7.0), 50 mM NaCl, 2.5 mM CaCl2, 10 mM MgCl2, 1 U 
DNaseI (Takara bio Inc., Tokyo, japan), 40 µg phosphodies-
terase I (Sigma-Aldrich, St. Louis, mo, USA), 2 U alkaline 
phosphatase (Nippon gene Co., Ltd., Tokyo, japan) and 10 µg 
extracted DNA at 37˚C for 2 h. After the reaction, 20 µl of 
4.2 N PCA was added to each reaction mixture and centrifuged 
at 15,000 rpm for 3 min. Sixty microliters of 1 m k2HPO4 was 
added to each sample for neutralization and centrifugation was 
performed to remove debris. The supernatant was analyzed by 
HPLC system with oDS reverse phase column (250x4.6 mm, 
5 µm; Phenomenex, Shimadzu gLC Ltd., Tokyo, japan), under 
the analytical method with eluent A [10 mM sodium phosphate 
(pH 6.8), 5% CH3CN], eluent b [10 mm sodium phosphate 
(pH 6.8), 60% CH3CN], at a solvent flow rate of 1.0 ml/min in 
a gradient elution as follows: b 0% from 0 to 5 min, b 0-20% 
from 5 to 10 min, b 20% from 10 to 15 min, b 20-70% from 
15 to 20 min, b 70% from 20 to 25 min, b 70-0% from 25 to 
25.1 min, and b 70-0% from 25.1 to 35 min.
Measurement of deoxyuridine monophosphate (dUMP) in 
tumor tissues of mouse xenografts. Collected tumors were 
homogenized with 0.48 N PCA and centrifuged for 5 min at 
2,000 rpm. Supernatants were collected and centrifuged for 
10 min at 15,000 rpm. Two volumes of 0.5 N tri-n-octylamine 
in CH2Cl2 were added and again centrifuged for 3 min at 
15,000 rpm; the supernatant was then analyzed using HPLC 
system with oDS reverse phase column (250x4.6 mm, 5 µm; 
Phenomenex), under the analytical method with eluent A 
(10 mM KH2PO4, 10 mm TbA-oH, 0.25% methanol: 50 mm 
KH2PO4, 10 mm TbA-oH, 30% methanol = 6:4, pH 6.7), and 
eluent b (50 mm kH2PO4, 10 mm TbA-oH, 30% methanol, 
pH 6.7) at a solvent flow rate 0.80 ml/min in a 175-min gradient 
elution as follows: b 1-23% from 0 to 20 min, b 23-45% from 
20 to 130 min, b 45-99% from 130 to 150 min, b 99-99% from 
150 to 160 min, b 99-1% from 160 to 160.1 min, and b 1-1% 
from 160.1 to 175 min.
In vivo survival following introduction of xenografts. KM20C 
cell suspensions were prepared from in vitro cell culture and 
injected into the peritoneal cavity at a volume of 1x107 cells 
on day 0. Drug treatment was started the next day (day 1). 
TAS-102 (150 mg/kg/day) was orally administered twice daily 
for 28 days, and S-1 (8.3 mg/kg/day) was also orally admin-
istered once daily for 28 days. The median increase of life 
span (ILS) was calculated as a survival index according to the 
following formula: ILS (%) = [(median survival time of treated 
group)/(median survival time of control group) - 1] x 100. The 
difference in the survival period distribution among groups 
was analyzed using the log-rank test.
Ki-67 staining and morphological analysis. All reagents and 
antibodies were obtained from Dako, Tokyo, japan. Heat-
induced antigen retrieval was performed in Target Retrieval 
Solution with an autoclave at 120˚C for 15 min. endogenous 
peroxidase activity was inhibited with Peroxidase-blocking 
Solution at room temperature (RT) for 5 min. The sections 
were then incubated at RT with the anti-Ki-67 mouse mono-
clonal antibody (clone mIb-1; 1:150 dilution). The sections 
were washed in wash buffer and incubated with EnVision at 
RT for 30 min. The reaction products were visualized with 
a liquid diaminobenzidine substrate. The nuclei were lightly 
counterstained with hematoxylin.
Statistical analysis. All statistical analyses were performed 
using SAS (SAS Institute, Cary, NC, USA). A P-value <0.05 
was considered to indicate a statistically significant result.
Results
Comparison of FTD and FdUrd effects on cell growth and 
TS activity. we first compared the degree of growth inhibition 
and TS inhibition elicited by FTD and FdUrd following 24 
and 72 h drug exposures. Table I shows the IC50 values derived 
from cell growth assays under these conditions. The cytotox-
icity of FdUrd was 40.7-fold lower after the 24-h treatment 
when compared with 72-h treatment. Notably, the magnitude 
of this difference with respect to duration of drug exposure 
was much lower (2.7-fold) in the case of FTD treatment.
both FTD and FdUrd can inhibit TS (15). we therefore 
compared the amount of dTTP accumulation in HeLa cells 
Table I. growth inhibitory effect of the FTD and FdUrd on 
HeLa cells following continuous or intermittent treatment.
 Treatment
Compounds duration (h) IC50a (µM) Ratiob
FTD 24 13.4 2.7
 72 4.9
FdUrd 24 37.1 41.2
 72 0.9
In the 72-h treatment experiment, HeLa cells were treated with FTD 
or FdUrd continuously for 72 h. In the 24-h treatment experiment, 
the drug was washed out at 24 h and replaced with drug-free medium 
for a further 48 h. aConcentrations that gave 50% growth inhibition; 
bthe IC50 ratio of 24- and 72-h treatment. FTD, trifluridine; FdUrd, 
fluorodeoxyuridine.
TANAKA et al:  PReCLINICAL eVALUATIoN oF TAS-102 ANTITUmoR meCHANISmS2322
after treatment with cytotoxic concentrations of FTD and 
FdUrd as an index of the TS inhibitory effect (16) (Fig. 1).
The dTTP levels in HeLa cells were markedly decreased 
after a 24-h treatment with either FTD or FdUrd. The dTTP 
pools did not reach pre-treatment levels following washout of 
FdUrd. In contrast, the dTTP pool in HeLa cells was restored 
to untreated levels between 6 and 24 h following washout of 
FTD. These results indicate that FTD-dependent inhibition of 
TS is reversible, and we therefore infer that inhibition of TS is 
not the major mechanism by which FTD exerts its cytotoxic 
effect.
Comparison of incorporation of FTD and other nucleoside 
analogs into DNA. we next compared the DNA incorpora-
tion level of FTD to that of other nucleoside analogs, namely, 
FdUrd, Ara-C and dFdC, as they are known to be incorporated 
into DNA (17). Incorporation of tritium-labeled nucleosides 
at concentrations that induced the same level of cytotoxicity 
was allowed to proceed for 4 h (Fig. 2). The amount of FTD 
incorporation (0.50±0.05 pmol/µg DNA) was significantly 
higher than that of Ara-C 0.04±0.0001 pmol/µg DNA, dFdC 
0.01±0.01 pmol/µg DNA and FdUrd 0.001±0.00004 pmol/µg 
DNA.
Comparison of the in vivo antitumor activity, DNA incorpora-
tion level and dUMP accumulation following delivery of FTD 
via oral or continuous infusion routes. To translate our in vitro 
findings to a more relevant model, FTD was administered by 
oral and continuous infusion routes at either the maximal 
tolerated dose (MTD) or 2/3X MTD for 14 days of treatment.
As shown in Table II, considerably higher doses of FTD 
were tolerated when the drug was administered orally rather 
than as a continuous infusion. For example, the change in 
body weight (-8.8±11.1%) with 50 mg/kg/day of oral FTD was 
similar to the change (7.9±12.0%) induced by 2 mg/kg/day of 
infusion FTD. Additionally, oral administration of FTD had 
a stronger antitumor effect than continuous infusion of FTD 
at the mTD (Table II). As an example, 50 mg/kg/day FTD 
oral administration gave an IR of 70.8% whereas 2 mg/kg/day 
Figure 1. dTTP accumulation in HeLa cells after washout of FTD and FdUrd. 
Following 24-h FTD or FdUrd treatment, the drug was washed out and dTTP 
was measured by HPLC analysis as described in Materials and methods. 
open and closed columns show dTTP accumulation by FTD and FdUrd 
treatment, respectively. The doses of FTD (2.5 µm) and FdUrd (0.01 µm) 
used were the IC50 values for the 72-h exposure. FTD, trifluridine; FdUrd, 
fluorodeoxyuridine.
Figure 2. DNA accumulation of various antitumor nucleosides. NUgC-3 
cells were treated for 4 h with each drug, and the amount that was incorpo-
rated into DNA was measured. The values are the means and the error bars 
are SD (n=3). The IC50 values of each drug after a 72-h treatment were chosen 
for this experiment (FTD 2.6 µm, FdUrd 0.10 µm, Ara-C 0.22 µm and dFdC 
0.0045 µm; data not shown). FTD, trifluridine; FdUrd, fluorodeoxyuridine; 
Ara-C, cytarabine; dFdC, gemcitabine.
Table II. Antitumor efficacy of FTD in human breast cancer xenografts following oral administration or continuous infusion.
  RTVa IRb bwCc
Treatment Administration route  (mean ± SD)  (%) (%, mean ± SD)
Control - 18.9±3.9 - 17.6±8.1
50 mg/kg/day FTD p.o. (b.i.d.) 5.5±1.0e 70.8 -8.8±11.1
75 mg/kg/day FTD p.o. (b.i.d.) 2.4±0.8e 87.5 -23.9±4.4
2.0 mg/kg/day FTD c.i. 13.5±4.7d 28.7 7.9±12.0
3.0 mg/kg/day FTD c.i. 7.9±1.3e 58.2 -13.6±9.1
FTD was administered for 14 days via each administration route. aRelative tumor volume (RTV) on day 15; btumor growth inhibition ratio (IR) 
on day 15; crelative body weight change (bwC) between day 0 and 15; dP<0.05, eP<0.01 according to Dunnett's test; p.o., per os; b.i.d., bis in 
die; c.i., continuous infusion. FTD, trifluridine.
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FTD continuous infusion produced an IR of only 28.7%. 
Slight tumor shrinkage and tumor growth suppression was 
observed after FTD oral administration (Fig. 3A). Consistent 
with the above results, the amount of FTD incorporated 
into the DNA of xenograft tumor cells was higher after oral 
administration (p.o., 50 and 75 mg/kg/day FTD, 17.34±3.90 
and 24.23±0.50 pmol/µg DNA respectively; c.i. 2.0 and 
3.0 mg/kg/day FTD, 2.56±0.66 and 3.68±0.02 pmol/µg DNA, 
respectively). As an index of TS activity, we also evaluated 
dUmP accumulation in tumor tissues, as its levels increase 
when TS is inhibited (18). As shown in Fig. 3C, dUmP levels 
increased during continuous infusion treatment. The increase 
reached high level following continuous infusion treatment 
(208.9 nmol/g). on the other hand, the dUmP level after oral 
administration increased transiently, and reverted to almost 
basal level (39 nmol/g) at 24 h.
Relationship between TAS-102 antitumor activity and the 
amount of FTD incorporation into tumor DNA. Since inhibi-
tion of TS did not appear to correlate with the antitumor activity 
of FTD, we hypothesized that direct interaction of the drug 
with DNA may contribute to its mechanism of action. TAS-102 
(150 mg/kg/day) was orally administered to mice harboring 
xenografts in two daily doses for 14 days (Table III). This 
regimen was effective against xenografts derived from a broad 
range of tumor cell types. Moreover, inclusion of HPLC analysis 
at day 7 revealed a positive correlation between the antitumor 
activity of TAS-102 and the amount of FTD incorporated 
into DNA (Pearson correlation coefficient r=0.92, R2=0.84, 
P=0.0013 by Pearson correlation coefficient test, Fig. 4).
FTD incorporation into DNA of a colon cancer-derived xeno-
graft following TAS-102 treatment. To investigate the kinetics 
of FTD incorporation into DNA, we followed the process 
during TAS-102 treatment of mice harboring KM20C human 
colon cancer xenografts (Fig. 5A and b). TAS-102 treatment 
(150 mg/kg/day, twice daily for 14 days) was compared to oral 
administration of S-1 once daily for 14 days. TAS-102 and S-1 
had similar antitumor effects (IR of 50.2 and 51.4%, respec-
tively). FTD accumulated in the DNA of km20C xenografts 
in a time-dependent manner throughout the administration of 
TAS-102. Compared to S-1 treatment, the growth suppressive 
effect of TAS-102 appeared more sustained (Fig. 5A).
Figure 3. In vivo analysis of FTD accumulation and activity in xenograft 
models. FTD was administered by daily oral administration or continuous 
infusion for 14 day to mice subcutaneously implanted with human breast 
cancer mX-1. (A) growth curve of xenografts. The tumor volume was mea-
sured twice a week and values indicate the means ± SD of the RTV (n=6-7). 
(b) The amount of FTD incorporated into DNA extracted from mX-1 was 
measured using HPLC analysis. Tumor for analysis of FTD accumulation 
was corrected at day 7. The values indicate the means ± SD (n=3). (C) The 
dUmP levels extracted from mX-1 were also measured using HPLC analysis. 
FTD was administered by oral administration at 0 h or continuous infusion 
from 0-24 h. FTD, trifluridine; dUmP, deoxyuridine monophosphate.
Table III. Antitumor efficacy of TAS-102 and DNA incorpora-
tion of FTD in xenografts derived from various cell types.
  IRa FTD incorporated
Tumor origin (%) into DNA
DLD-1 CRC 7.3 13.9
HT-29 CRC 17.2 13.8
SW480 CRC 26.4 10.4
HCT116 CRC 47.6 16.5
KM20C CRC 70.5 22.0
Lu-134 SCLC 75.8 21.8
mC-2 bC 58.0 21.3
mX-1 bC 86.9 25.7
TAS-102 was orally administered twice daily for 14 days at 150 mg/kg/
day. Tumor for analysis of FTD accumulation was collected at day 7. 
aTumor growth inhibition ratio on day 15. CRC, colorectal cancer; 
SCLC, small cell lung cancer; bC, breast cancer; FTD, trifluridine.
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TAS-102 prolongs survival in mice bearing human colon 
cancer xenografts. To determine whether TAS-102 could 
prolong survival, we used mice implanted with km20C xeno-
grafts (Fig. 6). The median survival time of control, TAS-102 
and S-1 administered group was 38, 70 and 44 day respec-
tively, and the ILS of TAS-102 and S-1 were 86.7 and 17.3%. 
TAS-102 significantly prolonged the survival of mice when 
compared to control (P<0.01), S-1 (P<0.01) as determined by 
the log-rank test.
Ki-67 staining and morphological analysis. To further charac-
terize the growth suppressive activity of TAS-102 in vivo, we 
performed immunohistochemical staining for Ki-67 (a marker 
of proliferating cells), as well as morphological analysis 
(Fig. 7A and b). Tumor samples were collected from xeno-
grafts following a 14-day TAS-102 treatment. Ki-67 staining 
intensity was markedly decreased in most cells. Notably, we 
also observed a swelling of nuclei in the tumors treated with 
TAS-102.
Discussion
FTD exhibits two major cellular activities, namely, inhibition 
of TS and incorporation into DNA. In the present study, we 
focused on determining which of these two activities plays the 
major role in the antitumor activity of TAS-102.
we first noted that both short- and long-term FTD treat-
ments are cytotoxic; however, TS activity was only sustained 
by long-term treatment. In contrast, even short-term FdUrd 
treatment was sufficient to block TS activity, whereas the cyto-
toxicity of short-term FdUrd was diminished. This is likely 
since fluorodeoxyuridine monophosphate (FdUmP) inhibits 
TS by forming a covalent bond, whereas FTD monophos-
phate (F3dTMP) inhibits TS in a reversible manner (15), and 
short-term TS inhibition is not sufficient to exert cytotoxicity. 
We suggest, therefore, that the growth inhibition after FTD 
Figure 5. Antitumor activity of TAS-102 and S-1 and the amount of FTD 
incorporation into colon cancer xenograft DNA. TAS-102 (150 mg/kg/day) 
was administered twice daily for 14 days. S-1 (8.3 mg/kg/day) was adminis-
tered once daily for 14 days. (A) Open circles, triangles and squares indicate 
control, TAS-102 and S-1 groups, respectively. (b) Amount of FTD incorpo-
rated into DNA following TAS-102 treatment. The values are the means ± SD 
(n=2 to 3). FTD, trifluridine.
Figure 6. TAS-102 prolongs the survival of mice harboring colon cancer 
xenografts. km20C colon cancer cells were implanted into the peritoneal 
cavity of nude mice at a volume of 1x107 cells on day 0. All compounds were 
administered from day 1 to 28. TAS-102 (150 mg/kg/day) was administered 
twice daily. S-1 (8.3 mg/kg/day) was administered once daily. Open circles, 
triangles and squares indicate control, TAS-102 and S-1 groups, respectively.
Figure 4. Relationship between the antitumor activity of TAS-102 and the 
amount of FTD incorporated into DNA. The amount of FTD incorporated 
into DNA in each tumor sample is plotted on the horizontal axis, and the IRs 
of each antitumor study is plotted on the vertical axis. All data are shown in 
Table III. A positive correlation was observed between the amount of FTD 
incorporated into the DNA of tumor cells and the antitumor effect of TAS-102 
(Pearson correlation coefficient r=0.92, R2=0.84, P=0.0013). FTD, trifluridine; 
IRs, inhibition rates.
ONCOLOGY REPORTS  32:  2319-2326,  2014 2325
washout is likely due to DNA incorporation rather than TS 
inhibition. There are reports that FdUrd can be incorporated 
into DNA (19). However, fluorodeoxyuridine triphosphate 
(FdUTP) is efficiently degraded by deoxyuridine 5'-triphos-
phate diphosphohydrolase (dUTPase) (20). In the present study, 
we confirmed that the amount of FTD incorporation into DNA 
was much higher than FdUrd and other antitumor nucleosides. 
We thus infer that FTD and its cellular derivatives may be less 
prone to pathways that would otherwise reduce their ability to 
incorporate to DNA.
Secondly, both the amount of FTD incorporation into DNA 
and antitumor activity was higher, yet the TS inhibitory activity 
was lower, when the drug was orally delivered. We infer that 
persisting low concentrations of FTD following continuous 
infusion block DNA synthesis via inhibition of TS, and this 
leads to a small amount of FTD incorporation into DNA, and 
unwanted side-effects. Coincidentally, little amount of FTD 
incorporates into DNA, since DNA synthesis is inhibited by 
TS persisting inhibition. by contrast, oral administration does 
not appear to inhibit TS chronically, and, therefore, DNA 
synthesis is less affected and FTD incorporates into DNA 
during DNA synthesis. It is reported that intracellular F3TTP 
concentrations reach a plateau after 8 h, and decline after 
washout (21). From these considerations, we suggest that daily 
oral administration of FTD could be a suitable regimen for 
antitumor treatments.
A significant caveat is that FTD is degraded when adminis-
tered orally. Indeed, the activity of TP in the liver of monkeys 
and humans is high, which can negatively affect systemic drug 
concentrations. In the present study, a positive correlation was 
observed between the level of FTD incorporated into tumor 
cell DNA and the antitumor activity of TAS-102 toward various 
xenografts. This relationship suggests that FTD incorporation 
into DNA is the major mechanism underlying the antitumor 
activity of TAS-102. Notably, the antitumor effect of TAS-102 
is sustained after administration (Fig. 5A), and a similar result 
was observed following FTD oral administration (Fig. 3A). 
This persistent antitumor activity likely accounts for the ability 
of TAS-102 to prolong the survival of xenograft-bearing mice. 
FTD is incorporated in place of thymidine bases in DNA (19), 
and this only slightly destabilizes the DNA duplex (22); it 
may alter DNA-protein interactions and cause nuclei swelling 
due to nucleosomal abnormality. Thus, the ability of FTD to 
accumulate in the DNA of tumor cells without causing imme-
diate catastrophic consequences may allow it to affect tumor 
cells in a chronic and persistent manner. bijnsdorp et al (23) 
stated that mechanisms by which FTD induces cell death are 
distinct from those elicited by 5-FU. It was also reported that 
TAS-102 monotherapy significantly improved overall survival 
for patients with mCRC and who were insensitive to fluoro-
pyrimidine-based standard therapies (10). Further analyses 
are needed to elucidate the mechanisms responsible for the 
cytotoxicity of FTD following its incorporation into DNA.
In conclusion, we suggest that, due to its unique mechanism 
of action, which is distinct from that of existing 5-FU deriva-
tives, TAS-102 has potential as a potent therapeutic option for 
malignancies that are insensitive to fluoropyrimidine-based 
therapy.
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